Opinion Statement Interest in the negative symptoms of schizophrenia has increased rapidly
over the last several decades, paralleling a growing interest in functional, in addition to …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

The activation of the N-methyl D-aspartate receptor (NMDAR) is controlled by a glutamate-
binding site and a distinct, independently regulated, co-agonist-binding site. In most brain …

The clinical development of selective alpha-7 nicotinic acetylcholine receptor (α7 nAChR)
agonists has hitherto been focused on disorders characterized by cognitive deficits (eg …

Schizophrenia is a major mental illness characterized by positive and negative symptoms,
and by cognitive deficit. Although cognitive impairment is disabling for patients, it has been …

The marine environment harbors a vast number of species that are the source of a wide
array of structurally diverse bioactive secondary metabolites. At this point in time, roughly …

Schizophrenia is considered primarily as a cognitive disorder. However, functional
outcomes in schizophrenia are limited by the lack of effective pharmacological and …

Research into the neurobiological processes that may lead to the onset of schizophrenia
places growing emphasis on the glutamatergic system and brain development. Preclinical …

Critical illnesses and injuries are recognized as major threats to human health, and they are
usually accompanied by uncontrolled inflammation and dysfunction of immune response …

Introduction The prevalence of tobacco use in the population with schizophrenia is
enormously high. Moreover, nicotine dependence is found to be associated with symptom …